Table 1. Summary of experimental data.
| Liver injury | No. of mice | Type and no. of donor cells | Donor derived cells in peripheral blood, % | Weeks from BM transplantation to analysis | Weeks from the end of CCl4 to analysis | Donorderived hepatocytes* or nodules observed | Y chromosomepositive hepatocyte nuclei/hepatocytes analyzed |
|---|---|---|---|---|---|---|---|
| Transplantation → CCl4 liver injury | |||||||
| 0.02 ml/kg × 8 times | 1 | GFP (1 × 106 BMMNC) | 95 (12 w) | 12 | 4 | 0 | 1/130,000 |
| 0.02 ml/kg × 8 times | 1 | LacZ (1 × 106 BMMNC) | 92 (4 w) | 12 | 4 | 0 | 2/60,000 |
| 0.02 ml/kg × 8 times | 1 | GFP (1 × 106 BMMNC) | 96 (12 w) | 16 | 8 | 0 | 1/140,000 |
| 0.02 ml/kg × 8 times | 1 | LacZ (1 × 106 BMMNC) | 91 (4 w) | 16 | 8 | 0 | 1/80,000 |
| CCl4 liver injury → transplantation (without preparative irradiation) | |||||||
| 0.02 ml/kg × 8 times | 2 | GFP (1 × 105 BMC) | 0 (4 w) | 4 | 4 | 0 | |
| 0.02 ml/kg × 8 times | 2 | LacZ (1 × 105 BMC) | 0 (4 w) | 4 | 4 | 0 | |
| 0.2 ml/kg × 8 times | 2 | GFP (1 × 107 BMC) | ND | 4 | 4 | 0 | |
| 1.0 ml/kg × 8 times | 2 | GFP (1 × 107 BMC) | 0 (2 w), ND | 2,4 | 2,4 | 0 | |
| TgN(Alb1Plau) | 1 (neonate) | GFP (1 × 106 BMC) | 17 (13 w) | 15 | 0 | ||
| TgN(Alb1HBV) | 1 | GFP (1 × 107 BMC) | 44 (11 w) | 13 | 0 | ||
| TgN(Alb1HBV) | 1 | GFP (1 × 107 BMC) | 97 (7 w) | 23 | 0 | ||
| TgN(Alb1HBV) | 1 | LacZ (5 × 106 BMC) | ≈100 (7 w) | 32 | 0 | ||
| TgN(Alb1HBV) + CDE† | 1 (neonate) | GFP (1 × 106 BMC) | 30 (9 w) | 47 | 0 | ||
| TgN(Alb1HBV) + CDE† | 1 (neonate) | GFP (1 × 106 BMC) | 18 (9 w) | 47 | 0 | ||
ND, not done; BMMNC, BM mononuclear cells.
*
Sixty sections containing 1.5 × 106 hepatocytes on average were analyzed per liver.
†
CDE, choline-deficient, ethionine-supplemented diet.